JPMorgan Chase & Co. Boosts Holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB)

JPMorgan Chase & Co. lifted its stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) by 5,137.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,509 shares of the biopharmaceutical company’s stock after acquiring an additional 3,442 shares during the period. JPMorgan Chase & Co. owned 0.06% of Assembly Biosciences worth $53,000 as of its most recent SEC filing.

Separately, FMR LLC raised its holdings in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 3,635 shares during the period. Institutional investors and hedge funds own 19.92% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Friday, December 27th.

Assembly Biosciences Trading Down 1.5 %

ASMB stock opened at $13.80 on Tuesday. Assembly Biosciences, Inc. has a 1 year low of $9.84 and a 1 year high of $19.93. The stock’s fifty day moving average is $15.48 and its two-hundred day moving average is $15.75.

Insider Buying and Selling

In other news, Director Michael Houghton purchased 3,202 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were bought at an average price of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.10% of the stock is owned by corporate insiders.

Assembly Biosciences Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.